Optimized GMP-grade Wharton's jelly's mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention.

Fiche publication

Date publication

septembre 2025

Journal

Current research in translational medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle , Pr RUBIO Marie Thérèse , Dr D'AVENI-PINEY Maud , Dr POCHON Cécile , Dr DE ISLA Natalia , Dr PAGLIUCA Simona , Dr NOTARANTONIO Anne-Béatrice

Tous les auteurs :
Pochon C, Perouf R, Notarantonio AB, Bertrand A, Charif N, Marcelo CB, Fouquet G, Cauchois G, Bensoussan D, Moulin D, Pagliuca S, de Isla N, Sartelet H, D'Aveni M, Rubio MT

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40957136

Résumé

Wharton's jelly mesenchymal stromal cells (WJ-MSCs) are multipotent cells derived from the umbilical cord with immunomodulatory properties, making them a promising candidate for cell-based therapies targeting immune-related diseases. Herein, we aim to optimize the conditions of use of clinical-grade WJ-MSCs manufactured according to Good Manufacturing Practice (GMP) for the prevention of graft versus host disease (GVHD) in a preclinical xenogeneic GVHD mouse model.